Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + trastuzumab + pertuzumab as neoadjuvant therapy for HER2-positive breast cancer
ChiCTR2500105365Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eribulin, trastuzumab and pertuzumab in breast cancer, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Total pathological complete response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500105365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105365.